Enveric BioScience CEO Dr Joseph Tucker joined Steve Darling from Proactive to share news the company has filed its 10th Patent application directed to tryptamine-based derivative molecules, thus completing its broad series of patents covering this family of compounds.
Tucker explains why this is so important as the company look at creation of novel molecules with improved pharmaceutical characteristics that are also protected by composition of matter, manufacturing, and method-of-use patent claim. Tucker also shared his thoughts on the company’s recent financing and groundbreaking trial they are doing with the University of Calgary.